Form 4: Amneal Pharmaceuticals Director Equity Transaction

Director Gautam Patel acquired 34,819 shares of Amneal Pharmaceuticals via restricted stock unit vesting and was granted 19,824 new units.

Summary

• Director Gautam Patel exercised 34,819 restricted stock units (RSUs) on May 7, 2026, converting them into Class A Common Stock.
• The reporting person was granted an additional 19,824 RSUs on May 6, 2026.
• Following these transactions, the director holds 1,643,963 shares of Class A Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it reflects standard director compensation and does not indicate a change in strategic direction or financial health.

Positives

• Director maintains a significant equity stake of 1,643,963 shares, aligning interests with shareholders.

Negatives

• None identified; this is a standard equity compensation event.

Risks

• None identified; this is a standard equity compensation event.

Future Outlook

The newly granted 19,824 restricted stock units are scheduled to vest on the later of the day preceding the first annual meeting of stockholders following the grant date or the first anniversary of the grant date.

Industry Context

StockSavvy.ai notes that this filing represents routine equity compensation for board members, which is standard practice in the pharmaceutical industry to ensure long-term alignment between directors and corporate performance.

Comparison to Industry Standards

• The use of RSU-based compensation for directors is consistent with standard corporate governance practices for mid-cap pharmaceutical companies.
• The holding level of 1.6 million shares represents a substantial commitment compared to typical non-executive director holdings in similar-sized firms.

Stakeholder Impact

• Shareholders may view the director's continued high level of ownership as a positive signal of confidence in the company's long-term prospects.

Next Steps

• Future vesting of the 19,824 restricted stock units granted on May 6, 2026.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Form 4, Insider Trading, Equity Compensation, Director Ownership